Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 107

1.

EZH2 in normal and malignant hematopoiesis.

Lund K, Adams PD, Copland M.

Leukemia. 2014 Jan;28(1):44-9. doi: 10.1038/leu.2013.288. Epub 2013 Oct 7. Review.

PMID:
24097338
[PubMed - indexed for MEDLINE]
2.

Multiple mechanisms deregulate EZH2 and histone H3 lysine 27 epigenetic changes in myeloid malignancies.

Khan SN, Jankowska AM, Mahfouz R, Dunbar AJ, Sugimoto Y, Hosono N, Hu Z, Cheriyath V, Vatolin S, Przychodzen B, Reu FJ, Saunthararajah Y, O'Keefe C, Sekeres MA, List AF, Moliterno AR, McDevitt MA, Maciejewski JP, Makishima H.

Leukemia. 2013 Jun;27(6):1301-9. doi: 10.1038/leu.2013.80. Epub 2013 Mar 14.

PMID:
23486531
[PubMed - indexed for MEDLINE]
3.

Overexpression of enhancer of zests homolog 2 in lymphoma.

Guo SQ, Zhang YZ.

Chin Med J (Engl). 2012 Oct;125(20):3735-9. Review.

PMID:
23075734
[PubMed - indexed for MEDLINE]
Free Article
4.

Epigenetic therapy with 3-deazaneplanocin A, an inhibitor of the histone methyltransferase EZH2, inhibits growth of non-small cell lung cancer cells.

Kikuchi J, Takashina T, Kinoshita I, Kikuchi E, Shimizu Y, Sakakibara-Konishi J, Oizumi S, Marquez VE, Nishimura M, Dosaka-Akita H.

Lung Cancer. 2012 Nov;78(2):138-43. doi: 10.1016/j.lungcan.2012.08.003. Epub 2012 Aug 25.

PMID:
22925699
[PubMed - indexed for MEDLINE]
Free PMC Article
5.

Phosphorylation of EZH2 activates STAT3 signaling via STAT3 methylation and promotes tumorigenicity of glioblastoma stem-like cells.

Kim E, Kim M, Woo DH, Shin Y, Shin J, Chang N, Oh YT, Kim H, Rheey J, Nakano I, Lee C, Joo KM, Rich JN, Nam DH, Lee J.

Cancer Cell. 2013 Jun 10;23(6):839-52. doi: 10.1016/j.ccr.2013.04.008. Epub 2013 May 16.

PMID:
23684459
[PubMed - indexed for MEDLINE]
Free PMC Article
6.

EZH2 is required for breast and pancreatic cancer stem cell maintenance and can be used as a functional cancer stem cell reporter.

van Vlerken LE, Kiefer CM, Morehouse C, Li Y, Groves C, Wilson SD, Yao Y, Hollingsworth RE, Hurt EM.

Stem Cells Transl Med. 2013 Jan;2(1):43-52. doi: 10.5966/sctm.2012-0036. Epub 2012 Dec 27.

PMID:
23283488
[PubMed - indexed for MEDLINE]
Free PMC Article
7.

Promotion of glioblastoma cell motility by enhancer of zeste homolog 2 (EZH2) is mediated by AXL receptor kinase.

Ott M, Litzenburger UM, Sahm F, Rauschenbach KJ, Tudoran R, Hartmann C, Marquez VE, von Deimling A, Wick W, Platten M.

PLoS One. 2012;7(10):e47663. doi: 10.1371/journal.pone.0047663. Epub 2012 Oct 15.

PMID:
23077658
[PubMed - indexed for MEDLINE]
Free PMC Article
8.

Aberrant expression of EZH2 is associated with pathological findings and P53 alteration.

Shiogama S, Yoshiba S, Soga D, Motohashi H, Shintani S.

Anticancer Res. 2013 Oct;33(10):4309-17.

PMID:
24122997
[PubMed - indexed for MEDLINE]
9.

The Polycomb group (PcG) protein EZH2 supports the survival of PAX3-FOXO1 alveolar rhabdomyosarcoma by repressing FBXO32 (Atrogin1/MAFbx).

Ciarapica R, De Salvo M, Carcarino E, Bracaglia G, Adesso L, Leoncini PP, Dall'Agnese A, Walters ZS, Verginelli F, De Sio L, Boldrini R, Inserra A, Bisogno G, Rosolen A, Alaggio R, Ferrari A, Collini P, Locatelli M, Stifani S, Screpanti I, Rutella S, Yu Q, Marquez VE, Shipley J, Valente S, Mai A, Miele L, Puri PL, Locatelli F, Palacios D, Rota R.

Oncogene. 2014 Aug 7;33(32):4173-84. doi: 10.1038/onc.2013.471. Epub 2013 Nov 11.

PMID:
24213577
[PubMed - indexed for MEDLINE]
10.

EZH2 overexpression in natural killer/T-cell lymphoma confers growth advantage independently of histone methyltransferase activity.

Yan J, Ng SB, Tay JL, Lin B, Koh TL, Tan J, Selvarajan V, Liu SC, Bi C, Wang S, Choo SN, Shimizu N, Huang G, Yu Q, Chng WJ.

Blood. 2013 May 30;121(22):4512-20. doi: 10.1182/blood-2012-08-450494. Epub 2013 Mar 25.

PMID:
23529930
[PubMed - indexed for MEDLINE]
Free Article
11.

Enhancer of zeste homolog 2 is overexpressed and contributes to epigenetic inactivation of p21 and phosphatase and tensin homolog in B-cell acute lymphoblastic leukemia.

Chen J, Li J, Han Q, Sun Z, Wang J, Wang S, Zhao RC.

Exp Biol Med (Maywood). 2012 Sep;237(9):1110-6. Epub 2012 Sep 6.

PMID:
22956625
[PubMed - indexed for MEDLINE]
12.

Inhibition enhancer of zeste homologue 2 promotes senescence and apoptosis induced by doxorubicin in p53 mutant gastric cancer cells.

Bai J, Ma M, Cai M, Xu F, Chen J, Wang G, Shuai X, Tao K.

Cell Prolif. 2014 Jun;47(3):211-8. doi: 10.1111/cpr.12103. Epub 2014 Apr 16.

PMID:
24738879
[PubMed - indexed for MEDLINE]
13.

EZH2: a pivotal regulator in controlling cell differentiation.

Chen YH, Hung MC, Li LY.

Am J Transl Res. 2012;4(4):364-75. Epub 2012 Oct 10.

PMID:
23145205
[PubMed]
Free PMC Article
14.

The oncogenic polycomb histone methyltransferase EZH2 methylates lysine 120 on histone H2B and competes ubiquitination.

Kogure M, Takawa M, Saloura V, Sone K, Piao L, Ueda K, Ibrahim R, Tsunoda T, Sugiyama M, Atomi Y, Nakamura Y, Hamamoto R.

Neoplasia. 2013 Nov;15(11):1251-61.

PMID:
24339737
[PubMed - indexed for MEDLINE]
Free PMC Article
15.

In aggressive variants of non-Hodgkin lymphomas, Ezh2 is strongly expressed and polycomb repressive complex PRC1.4 dominates over PRC1.2.

Abd Al Kader L, Oka T, Takata K, Sun X, Sato H, Murakami I, Toji T, Manabe A, Kimura H, Yoshino T.

Virchows Arch. 2013 Nov;463(5):697-711. doi: 10.1007/s00428-013-1428-y. Epub 2013 Aug 16.

PMID:
23948956
[PubMed - indexed for MEDLINE]
16.

EZH2 promotes malignant behaviors via cell cycle dysregulation and its mRNA level associates with prognosis of patient with non-small cell lung cancer.

Cao W, Ribeiro Rde O, Liu D, Saintigny P, Xia R, Xue Y, Lin R, Mao L, Ren H.

PLoS One. 2012;7(12):e52984. doi: 10.1371/journal.pone.0052984. Epub 2012 Dec 31.

PMID:
23300840
[PubMed - indexed for MEDLINE]
Free PMC Article
17.

Epigenetic regulation of cell adhesion and communication by enhancer of zeste homolog 2 in human endothelial cells.

Dreger H, Ludwig A, Weller A, Stangl V, Baumann G, Meiners S, Stangl K.

Hypertension. 2012 Nov;60(5):1176-83. doi: 10.1161/HYPERTENSIONAHA.112.191098. Epub 2012 Sep 10.

PMID:
22966008
[PubMed - indexed for MEDLINE]
Free Article
18.

Poorly differentiated synovial sarcoma is associated with high expression of enhancer of zeste homologue 2 (EZH2).

Changchien YC, Tátrai P, Papp G, Sápi J, Fónyad L, Szendrői M, Pápai Z, Sápi Z.

J Transl Med. 2012 Oct 30;10:216. doi: 10.1186/1479-5876-10-216.

PMID:
23110793
[PubMed - indexed for MEDLINE]
Free PMC Article
19.

Molecular mechanisms involved in the synergistic interaction of the EZH2 inhibitor 3-deazaneplanocin A with gemcitabine in pancreatic cancer cells.

Avan A, Crea F, Paolicchi E, Funel N, Galvani E, Marquez VE, Honeywell RJ, Danesi R, Peters GJ, Giovannetti E.

Mol Cancer Ther. 2012 Aug;11(8):1735-46. doi: 10.1158/1535-7163.MCT-12-0037. Epub 2012 May 23.

PMID:
22622284
[PubMed - indexed for MEDLINE]
Free PMC Article
20.

EZH2 inhibition as a therapeutic strategy for lymphoma with EZH2-activating mutations.

McCabe MT, Ott HM, Ganji G, Korenchuk S, Thompson C, Van Aller GS, Liu Y, Graves AP, Della Pietra A 3rd, Diaz E, LaFrance LV, Mellinger M, Duquenne C, Tian X, Kruger RG, McHugh CF, Brandt M, Miller WH, Dhanak D, Verma SK, Tummino PJ, Creasy CL.

Nature. 2012 Dec 6;492(7427):108-12. doi: 10.1038/nature11606. Epub 2012 Oct 10.

PMID:
23051747
[PubMed - indexed for MEDLINE]

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk